Clinical trials: Tislelizumab
Hepatocellular Carcinoma
Observation Study of Sequential Regorafenib Plus ICIs After HAIC for Advanced Hepatocellular Carcinoma
Hepatic artery infusion chemotherapy (HAIC) has shown promising outcomes in patients with advanced hepatocellular carcinoma (HCC). Some patients can be converted to loco-regional therapies after 4-6 cycles of HAIC treatment.
- Trial name
- NCT05573282
- Testing
- Regorafenib combine with ICIs
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumor
Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors
The purpose of this study is to evaluate the safety, immunogenicity and preliminary efficacy of engineered dendritic cells（eDCs）loaded with mKRAS antigen (CAT-101) alone or in combination with Tislelizumab (anti-PD-1 monoclonal…
- Trial name
- NCT07396090
- Testing
- eDC-KRAS vaccine, Tislelizumab
- Volunteers
- 13 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Hepatocellular Carcinoma
Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC
To explore the effects of lenvatinib in combination with tislelizumab with or without TACE in patients with hepatocellular carcinoma on survival, disease progression, and medication safety.
- Trial name
- NCT05842317
- Testing
- Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Gastric Cancer
Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer
To explore the efficacy of Tislelizumab combined with chemotherapy in the treatment of advanced gastric cancer after first-line resistance
- Trial name
- NCT05751265
- Testing
- Tislelizumab, 5Fu, Paclitaxel injection
- Volunteers
- 39 people
- Sponsor
- Fujian Cancer Hospital
Hepatocellular Carcinoma With PVTT
HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)
To estimate the safety and efficacy of hepatic artery infusion chemotherapy (HAIC) combine Tislelizumab and Lenvatinib (HAI-TIS-LEN) in the Treatment of hepatocellular carcinoma (HCC) with type IV(Vp4) portal vein tumor thrombus…
- Trial name
- HAI-TL (NCT06210334)
- Testing
- Tislelizumab, Lenvatinib
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Li Xiao Wei
RAS Mutation, Non-small Cell Lung Cancer (NSCLC)
This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.
This is an open-label, multicenter Phase Ib/II clinical study evaluating GFH276 in combination with tislelizumab plus pemetrexed/platinum based regimen as first-line therapy in participants with locally advanced or metastatic…
- Trial name
- GFH276X1203 (NCT07846358)
- Testing
- GFH276, with or without Tislelizumab, Pemetrexed
- Volunteers
- 84 people
- Sponsor
- Genfleet Therapeutics (Shanghai) Inc.
Upper Tract Urothelial Carcinoma
Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper Tract Urothelial Carcinoma
This is a prospective, multicentre, single-arm phase II study evaluating a response-adapted kidney-preserving strategy in patients with HER2-positive high-risk upper tract urothelial carcinoma (UTUC).
- Trial name
- NCT07584733
- Testing
- RC48 Combined With Tislelizumab
- Where
- China
- Volunteers
- 50 people
- Sponsor
- RenJi Hospital
Extensive-stage Small-cell Lung Cancer
Clinical Study on Using TCR to Predict the Effect of Tislelizumab + Chemotherapy in the First-line Treatment of ES-SCLC
This is a prospective observational clinical study designed to predict the therapeutic efficacy of first-line treatment with tislelizumab combined with standard chemotherapy in patients with ES-SCLC using TCR repertoire…
- Trial name
- ES-SCLC (NCT07244016)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Henan Cancer Hospital
Gastric Neoplasms, Gastroesophageal Adenocarcinoma
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy.
- Conditions
- Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
- Trial name
- HERIZON-GEA-01 (NCT05152147)
- Testing
- Zanidatamab, Tislelizumab, Trastuzumab
- Where
- 227 sites in Argentina, Australia and 31 more
- Volunteers
- 920 people
- Sponsor
- Jazz Pharmaceuticals
Gastroesophageal Cancer
Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer
The HER-OIC clinical trial is a Phase 1b/2a study investigating a new combination of treatments for patients with HER2-positive gastroesophageal cancer.
- Trial name
- HER-OIC (NCT07477444)
- Testing
- Zanidatamab Combined with Chemotherapy
- Volunteers
- 29 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Stomach Neoplasms, Gastric Cancer (Diagnosis)
Lymph Node Metastasis Pattern After Neoadjuvant Chemoimmunotherapy in LAGC
The purpose of this observational study is to learn how stomach cancer that has spread to nearby lymph nodes responds to standard chemotherapy combined with immunotherapy given before surgery.
- Conditions
- Stomach Neoplasms, Gastric Cancer (Diagnosis), Gastric Adenocarcinoma
- Trial name
- NCT07899775
- Testing
- Neoadjuvant SOX chemotherapy combined with PD-1 inhibitor
- Volunteers
- 103 people
- Sponsor
- Hainan General Hospital
Lung Carcinoma
A Study of SKB518 in Patients With Lung Cancer
This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB518 in patients with lung cancer.
- Trial name
- NCT07019675
- Testing
- SKB518, Tislelizumab, Carboplatin
- Where
- 17 sites in China
- Volunteers
- 192 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer
Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC
This study is a single-center, prospective, single-arm exploratory clinical study of hypofractionated radiotherapy followed by tislelizumab and anlotinib neoadjuvant and adjuvant therapy.
- Trial name
- NCT06379087
- Testing
- Anlotinib Hydrochloride Capsule, Tislelizumab Injection, Hypofractionated Radiotherapy
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Ji Yongling
Esophageal Squamous Cell Carcinoma
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
This study is a multicentre, randomised, parallel-controlled, open-label, 3 phase clinical trial. The subjects were untreated, unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma with low…
- Trial name
- NCT05919030
- Testing
- Intensity-modulated radiotherapy (IMRT), Tislelizumab, Cisplatin
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Renmin Hospital of Wuhan University
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
The purpose of this study was to determine the maximum tolerated dose (MTD), recommended dose for expansion (RDFE), safety and tolerability of BGB-10188 as monotherapy in participants with relapsed/refractory (R/R) mature B-cell…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT04282018
- Testing
- BGB-10188, Zanubrutinib, Tislelizumab
- Where
- 24 sites in Australia, China
- Volunteers
- 97 people
- Sponsor
- BeiGene
Immunotherapy
Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
To compare the efficacy of Neoadjuvant Chemoradiotherapy Combined With/without Tislelizumab in the Treatment of Locally Advanced Rectal Cancer
- Trial name
- NCT05479240
- Testing
- Tislelizumab, Capecitabine, oxaliplatin
- Volunteers
- 94 people
- Sponsor
- Fujian Cancer Hospital
NSCLC
A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
This is a randomized, positive controlled, open-Label and multicenter phase III study, to evaluate the efficacy and safety of Sosimerasib in combination with IN10018 versus anti-PD-1 monoclonal antibody in combination with…
- Trial name
- NCT07833202
- Testing
- Sosimerasib in combination with IN10018, Tislelizumab + Carboplatin + Pemetrexed
- Where
- China
- Volunteers
- 416 people
- Sponsor
- Shanghai Jeyou Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC
This prospective phase II randomized study is to determine the impact of thymosin alpha-1 on the concurrent chemoradiotherpay followed by immunotherapy consolidation in patients with locally advanced NSCLC by assessing the…
- Trial name
- NCT06139419
- Testing
- definitive radiotherapy, induction chemo-immunotherapy, concurrent chemotherapy
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Sun Yat-sen University
Nasopharangeal Cancer, Distant Metastasis
PD-1 Inhibitor Plus Chemotherapy Followed by Immediate Versus Salvage Locoregional Radiotherapy in De Novo Metastatic NPC
This phase III randomized trial evaluates PD-1 inhibitor plus chemotherapy followed by immediate versus salvage locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma.
- Trial name
- NCT07235319
- Testing
- Immediate locoregional radiotherapy, Salvage locoregional radiotherapy
- Where
- 5 sites in China
- Volunteers
- 260 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma by BCLC Stage
Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions
Liver cancer is the third leading cause of cancer-related deaths worldwide. The majority of primary liver cancers occur as hepatocellular carcinoma (HCC), the incidence of which is increasing in many parts of the world.
- Trial name
- HESTIA (NCT05622071)
- Testing
- Tislelizumab
- Where
- 10 sites in France
- Volunteers
- 50 people
- Sponsor
- UNICANCER